Heart Disease Trial, Recruiting NCT06154395 Sponsor: Harbin Medical University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06154395
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older.
  • People who have been newly diagnosed with a specific type of heart attack (called an anterior wall STEMI) where symptoms started within the last 6 hours, and who are being treated with an emergency procedure to open the blocked artery (called primary PCI).
  • People (or their legal representative) who understand what the study involves and have signed a consent form agreeing to take part.
  • People whose blocked artery (the one causing the heart attack) is in a native coronary artery with a vessel width estimated to be between 2.25 mm and 4.0 mm.
  • People whose blocked artery segment is located in a specific part of the main heart artery (the LAD), between its starting point and the second branch off it (confirm with trial site).
  • People whose artery, after initial treatment during the procedure, shows less than 90% blockage remaining and has good blood flow (a specific flow grade called TIMI 3).

Who may not be able to join:

  • People who have previously had open-heart bypass surgery (CABG).
  • People with a known history of a prior heart attack or prior PCI procedure.
  • People who received clot-dissolving medication (thrombolysis) before their PCI procedure.
  • People with severe liver or kidney disease, severe heart valve disease, or severe chronic lung disease (COPD).
  • People who are unable to have an MRI scan for any reason.
  • People with a known allergy to gadolinium contrast dye, or to any medications or materials used in the procedure, including components of drug-eluting stents, all P2Y12 inhibitor medications, or aspirin.
  • People whose life expectancy is estimated to be less than 12 months.
  • People who are pregnant or breastfeeding.
  • People whom the study doctor considers unsuitable for the trial for any other reason.
  • People who have other artery blockages that also need to be treated during the same procedure, in addition to the main blocked artery.
  • People with significant disease in the left main coronary artery (estimated blockage greater than 50%) that is not protected by a bypass graft.
  • People with widespread severe calcium build-up (more than 20 mm) or a completely blocked artery in certain other major heart arteries.
  • People with severely twisted or heavily calcified coronary arteries, or other conditions that may interfere with the use of imaging tools inside the artery during the procedure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bo Yu, M.D.; Ph.D., The Second Affiliated Hospital of Harbin Medical University

Phone: +86-13796626722

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Harbin Medical University
Registry
ClinicalTrials.gov
Start date
20 December 2023
Est. completion
31 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Microvascular obstruction (MVO) assessed by cardiac magnetic resonance imaging (CMR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov